Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,215 total articles
UMB Financial (UMBF) combines steady loan and deposit growth, improving profitability and a conservative balance sheet. At roughly $11.0B market cap, a P/E ~12 and low leverage, the risk/reward favors a long with a $166.50 target over the next 180 trading days, using a $131 stop to protect capital.
Prysmian agreed to acquire Atkore for $3.8 billion, adding U.S.-focused electrical products and potential higher-margin solutions to its cable-heavy portfolio. With Q2 signs of EBITDA acceleration and technicals stabilizing near the 10-day SMA, a measured long looks attractive for investors willing to hold through integration risk.
Zscaler beat revenue and EPS expectations on 09/03/2026 and shows healthy free cash flow, but the stock trades at a demanding EV/S ~8.8 and sits well below its 52-week high. This trade targets a mid-term rebound if guidance and ARR commentary sustain momentum, while protecting capital with a clear stop-loss below structural support.
Alpha Tau is a speculative biotech with a single-asset focus on glioblastoma multiforme (GBM). With a potentially pivotal data cadence concentrated before year-end, limited public float, and a therapy profile that could re-rate the company if efficacy signals appear, this is a directional trade that favors asymmetric upside versus defined downside.…
Meta rallied after the 09/03/2026 Muse Spark 1.3 demo, but the gap between model benchmarks and product monetization remains wide. With a $1.56T market cap, rich multiples, and limited days-to-cover for shorts, this trade aims to capture a mid-term reversion as investors reset expectations on near-term monetization and mark higher capex risk into R…
Rocket Lab's pullback has compressed an otherwise strong growth narrative into an actionable entry. With a $38.3B market cap, negative free cash flow of $371.1M and an elevated P/S, the name is not cheap — but near-term technical weakness and concentrated short interest create the conditions for a rebound if upcoming catalysts land. This trade targ…
Okta's Q2 print showed tangible momentum: $805M revenue (+11% YoY), adjusted EPS ahead, and AI-agent security sales accounting for ~30% of bookings. The stock is trading near its 52-week high and up strongly on momentum, so this is a tactically bullish trade that balances upside from accelerating enterprise adoption and middling valuation multiple.…
Broadcom's AI semiconductor business is already a multi-billion dollar earnings engine. Q3 showed $29.6B revenue with AI semiconductor sales of $16.7B (221% YoY), turning explosive top-line growth into free cash flow. The stock is digesting slightly softer Q4 guidance; that creates a tactical buying window for a long trade sized to tolerate short-t…
Ouster is moving beyond sensors into integrated perception platforms for vehicles, robots and defense systems. Recent manufacturing partnerships, sensor qualifications and accelerating revenue trends argue for upside from the current $35 area. This is a tactical long with a 180-trading-day horizon, entry at $35.50, target $50.00 and stop $29.00.
AAR (AIR) has benefited from a resurgent MRO market and accelerating sales growth, but technicals and modest free cash flow create a two-sided setup. This trade targets a measured long entry near current levels, with a defined stop below the recent swing low and a 180-trading-day upside target that captures mean-reversion toward the 52-week range.
Apple Hospitality REIT (APLE) offers a compelling mid-term trade: an attractive monthly yield (6.16%), conservative balance sheet (debt/equity ~0.51), and valuation metrics that leave upside if RevPAR and occupancy trends continue to normalize. Technicals show short-term weakness but room for mean reversion toward the 52-week high. Enter $15.68, ta…
Credo (CRDO) has been hit hard by the market’s short-term focus on margins and customer concentration despite accelerating top-line growth and a clear pathway to $600M+ optical revenue this year. I doubled my exposure at $170.13 because the fundamentals — 115% quarterly revenue growth, a $1.3B revenue base, and expanding optical demand — support a …
LENZ Therapeutics is a pre-commercial eye-drop company trading at a sub-$200M market cap after a rocky launch and heavy operating losses. The stock looks cheap relative to future milestone and royalty upside (notably an Everest Medicines Greater China deal worth up to $85M), but the company still burns cash and has weak near-term sales traction. Th…
PayPay is executing inorganic moves - partnerships, bank tie-ups, and merchant incentives - to capture structural cashless adoption in Japan. With a clear path to higher take-rates and payment volume, this trade aims to buy a pullback and hold through integration catalysts. Entry $8.50, target $12.50, stop $6.50 over a 180 trading-day horizon.
Jackson Financial (JXN) checks the boxes for a cash-rich insurer: sizable free cash flow ($5.885B), modest leverage (debt/equity 0.33), near-book valuation (P/B ~1.01) and a meaningful dividend. For investors willing to own the stock into the 2026-2027 earnings and capital return cycle, JXN offers asymmetric upside. Trade plan included.
Avalo Therapeutics' positive Phase 2 readout for abdakibart in hidradenitis suppurativa and a $375M financing have materially de-risked the story and created a clear development path toward Phase 3 and follow-on pipeline candidates. At a market cap near $1.02B and a current price of $19.16, the stock looks primed for a clinical re-rating while stil…
Nano Labs pivoting into AI chips and North America infrastructure has real upside if execution and non-GAAP metrics hold. The balance sheet and market cap (about $54M) imply low expectations. That creates an asymmetric mid-term trade: buy at current levels expecting a re-rate on product launches and partnerships, while respecting large GAAP volatil…
Equinor (EQNR) is trading near multi-year highs after a strong Q2 showing, an active buyback program and a healthy dividend. The company combines reliable cash flow from production with growth optionality in offshore wind and strategic North Sea positions. We recommend a long trade sized conservatively with a $42.33 entry, $39.00 stop and $52.00 ta…
Apple is trading near $321 after a pullback. With $136.7B in free cash flow, a premium but justifiable valuation (PE ~37.6), and improving product leadership under John Ternus, the risk-reward favors a measured long. This trade plan buys the thesis that Apple can extend compounding while keeping capital allocation disciplined.
<p>Volkswagen is executing the biggest strategic pivot in its modern history: a push from legacy combustion-volume maker to software-driven EV platform owner. The market still treats VW like a cyclical, low-growth carmaker, creating an asymmetric opportunity in the mid term. This trade idea lays out a clear entry at $36.00, a stop at $30.00 and a t…
Kraken Robotics plunged roughly 50% from recent highs, compressing downside and creating an asymmetric trade setup. This note lays out a mid-term (45 trading days) tactical long with a defined entry, stop and target, explains why the business matters, and frames the key catalysts and risks that will determine whether this recovery has legs.
Southwest (LUV) has the fundamentals and recent operational tailwinds to outpace peers into year-end. Ticket pricing power, disciplined buybacks and fleet refresh prospects support a rating upgrade. This is a tactical, mid-term long trade: entry $39.28, stop $35.50, target $48.00 (45 trading days primary horizon).
Nature's Sunshine (NATR) trades near $13.92 with zero debt, roughly $84.6M of net cash implied by enterprise value and market cap, steady free cash flow of ~$18M, and a sub-14 P/E. Technicals show oversold momentum and short interest is elevated — an attractive risk-reward for a mid-term swing trade.
Bristol Myers Squibb (BMY) looks inexpensive on fundamentals: ~15x P/E, ~$11.4B of free cash flow and a ~3.7% dividend yield. The chart has been choppy and momentum indicators have cooled, but that creates a cleaner entry for traders who want exposure to a large-cap pharma with a strong oncology and immunology franchise. This trade idea outlines a …
QumulusAI (QMLS) is a GPU-first cloud provider focused on underserved SMBs and enterprise supplemental compute. The stock is trading near its 52-week low at $5.62 with RSI in the high-20s, positive MACD histogram and outsized short volume. For disciplined traders, a mid-term swing long at $5.62 with a stop at $4.80 and a target of $10.00 offers asy…
